SCHEMBL1167389

SCHEMBL1167389

Cc1ccc(C)c(COC(=O)Nc2cnn(Cc3ccc(C(C)(F)F)o3)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 1/20 0.40
SCD O00767 3/20 0.39
SCD5 Q86SK9 2/20 0.39
MAPT P10636 2/20 0.38
HDAC3 O15379 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
KDM4E B2RXH2 5/20 0.37
HPGD P15428 4/20 0.37
HSD17B10 Q99714 3/20 0.37
CYP2C19 P33261 2/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1167395 0.91 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2SCDSCD5MAPT
SCHEMBL1166181 0.88 SCD (0.41) HCRTR1HCRTR2ALDH1A1SMN1; SMN2LMNA
SCHEMBL1166978 0.88 SMN1; SMN2 (0.42) HCRTR1HCRTR2ALDH1A1SMN1; SMN2SCD
SCHEMBL1166149 0.87 HCRTR2 (0.47) HCRTR1HCRTR2ALDH1A1SMN1; SMN2LMNA
SCHEMBL1166681 0.85 SCD5 (0.43) HCRTR1HCRTR2ALDH1A1SMN1; SMN2SCD
SCHEMBL1167290 0.85 HCRTR1 (0.54) HCRTR1HCRTR2ALDH1A1SMN1; SMN2LMNA
SCHEMBL1166111 0.84 TAS2R8 (0.38) HCRTR1HCRTR2ALDH1A1SMN1; SMN2LMNA
SCHEMBL1166886 0.84 SCD5 (0.43) ALDH1A1SMN1; SMN2SCDSCD5MAPT
SCHEMBL1166683 0.84 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2LMNAHTTSCD
SCHEMBL1167745 0.84 SCD (0.50) ALDH1A1SMN1; SMN2SCDSCD5HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP claimed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US claimed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US claimed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 EP claimed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 WO claimed
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 EP disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 HCRTR1 2862/4885HCRTR2 2700/4885ALDH1A1 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.